John Libbey Eurotext

Hématologie

Mutations de TP53 et traitement par décitabine dans les leucémies aiguës myéloïdes et les syndromes myélodysplasiques Volume 23, numéro 1, Janvier-Février 2017

  • [1] Lindsley R.C., Mar B.G., Mazzola E. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367-1376.
  • [2] Klepin H.D. Myelodysplastic syndromes and acute myeloid leukemia in the elderly. Clin Geriatr Med. 2016;32:155-173.
  • [3] Rücker F.G., Schlenk R.F., Bullinger L. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119:2114-2121.
  • [4] Fenaux, Mufti G.J., Hellstrom-Lindberg E. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-232.
  • [5] Dombret H., Seymour J.F., Butrym A. Blood. 2015;126:291-299.
  • [6] de Vos D., van Overveld W. Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol. 2005;84:3-8. Suppl 1